GlobeNewswire EN Nachrichten

 

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 ...

AUSTIN, Texas, March 09, 2026 (GLOBE NEWSWIRE) -- Asure Software, Inc. (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management software solutions, announced today that the Company will host a Fireside Chat on Asure's current perspective on artificial intelligence with Chairman & CEO Pat Goepel and CTO Yasmine Rodriguez on March 11, 2026 at 4:30PM ET....

Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter...

Oxford to Release Fourth Quarter Fiscal 2025 Results on March 26, 2026...

Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026...

SHAKOPEE, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (Nasdaq: CPHC) today reported financial results for the fourth quarter and full year ended December 31, 2025....

SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, March 23, 2026, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2025 and to highlight recent corporate progress....

AEON Biopharma Appoints John Bencich as Chief Financial Officer...

HOUSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Amplify Energy Corp. (NYSE: AMPY) (“Amplify,” the “Company,” “us,” or “our”) announced today updates to its strategic initiatives, year-end 2025 proved reserves, operating and financial results for the fourth quarter and full-year 2025, and full-year 2026 development plans and guidance for the Company....

ATLANTA, March 09, 2026 (GLOBE NEWSWIRE) -- Bitcoin Depot (Nasdaq: BTM) (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, will hold a conference call and live audio webcast on Monday, March 16th at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) to discuss its financial results for the fourth quarter and full year ended December 31, 2025. Bitcoin Depot plans to release its results before the market opens on the same day....

CapsoVision to Participate in the 38th Annual ROTH Conference...

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- StepStone Group Inc. (Nasdaq: STEP) today announced that its Board of Directors authorized a stock repurchase program of up to $100 million of the company's Class A common stock....

- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment -...

Net Asset Value of $8.09 Per Share as of December 31, 2025...

Conference call begins at 4:30 p.m. Eastern time today...

The RealReal, the world's largest online marketplace for authenticated luxury resale, today announced changes to its Board of Directors....

Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment...

NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Dianthus expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Dianthus....

VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that it has commenced an underwritten public offering of $500.0 million of its common shares, pursuant to its existing shelf registration statement. All of the common shares in this offering are being offered by Xenon. In addition, Xenon intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $75.0 million of common shares at the public offering price, less the underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed....

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025....